Back to trial detailsIntake questionnaire
A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer
Applying to MD Anderson Cancer Center · Houston, Texas
Answer a few short questions to share with the research team.
0 of 4 answered